Evidence map›Paper›PMID 31014245›Full record

ArticleBMC genomics2019

Comprehensive kinome NGS targeted expression profiling by KING-REX.

Giovanni Carapezza, Carlo Cusi, Ettore Rizzo, Laura Raddrizzani, Sebastiano Di Bella, Alessio Somaschini, Antonella Leone, Rosita Lupi, Margherita Mutarelli, Vincenzo Nigro and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Giovanni CarapezzaNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Carlo CusiNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Ettore RizzoDepartment of Electrical, Computer, and Biomedical Engineering, University of Pavia, Pavia, Italy.
Laura RaddrizzaniNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Sebastiano Di BellaNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Alessio SomaschiniNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Antonella LeoneNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Rosita LupiNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Margherita MutarelliTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy.
Vincenzo NigroTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy.
Diego di BernardoTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy.
Paolo MagniDepartment of Electrical, Computer, and Biomedical Engineering, University of Pavia, Pavia, Italy.
Antonella IsacchiNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy.
Roberta BosottiNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, MI, Italy. roberta.bosotti@nervianoms.com.ORCID http://orcid.org/0000-0002-5467-6212
Nerviano Medical Sciences · ITTelethon Institute Of Genetics And Medicine · ITUniversity of Pavia · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

DNA SAMPLE ANALYSIS27307C2007 · NIEHS · PI LEHMAN, TERESA · 2007 to 2007
$74k
Fondazione per la Ricerca Biomedica 2015-0010Ministero dell'Istruzione, dell'Università e della Ricerca PON R&C 2007-2013; PON project PON 01_02418NIEHS NIH HHS 27307C2007
6 · The paper itself

Abstract

backgroundProtein kinases are enzymes controlling different cellular functions. Genetic alterations often result in kinase dysregulation, making kinases a very attractive class of druggable targets in several human diseases. Existing approved drugs still target a very limited portion of the human 'kinome', demanding a broader functional knowledge of individual and co-expressed kinase patterns in physiologic and pathologic settings. The development of novel rapid and cost-effective methods for kinome screening is therefore highly desirable, potentially leading to the identification of novel kinase drug targets.

resultsIn this work, we describe the development of KING-REX (KINase Gene RNA EXpression), a comprehensive kinome RNA targeted custom assay-based panel designed for Next Generation Sequencing analysis, coupled with a dedicated data analysis pipeline. We have conceived KING-REX for the gene expression analysis of 512 human kinases; for 319 kinases, paired assays and custom analysis pipeline features allow the evaluation of 3'- and 5'-end transcript imbalances as readout for the prediction of gene rearrangements. Validation tests on cell line models harboring known gene fusions demonstrated a comparable accuracy of KING-REX gene expression assessment as in whole transcriptome analyses, together with a robust detection of transcript portion imbalances in rearranged kinases, even in complex RNA mixtures or in degraded RNA.

conclusionsThese results support the use of KING-REX as a rapid and cost effective kinome investigation tool in the field of kinase target identification for applications in cancer biology and other human diseases.

Indexed as

Gene Expression ProfilingGene FusionHigh-Throughput Nucleotide SequencingProtein KinasesRNA StabilityProtein KinasesKinome gene expressionNGS RNA targeted panel

Identifiers

PMID31014245
PMCPMC6480677
OpenAlexW2947496730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.